| |
Author |
Title |
Year |
Publication |
Volume  |
Pages |
Links |
|
|
Oliva, C.R.; Zhang, W.; Langford, C.; Suto, M.J.; Griguer, C.E. |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit |
2017 |
Oncotarget |
8 |
37568-37583 |
|
|
|
Roy, A.; Attarha, S.; Weishaupt, H.; Edqvist, P.-H.; Swartling, F.J.; Bergqvist, M.; Siebzehnrubl, F.A.; Smits, A.; Ponten, F.; Tchougounova, E. |
Serglycin as a potential biomarker for glioma: association of serglycin expression, extent of mast cell recruitment and glioblastoma progression |
2017 |
Oncotarget |
8 |
24815-24827 |
|
|
|
Brodie, S.; Lee, H.K.; Jiang, W.; Cazacu, S.; Xiang, C.; Poisson, L.M.; Datta, I.; Kalkanis, S.; Ginsberg, D.; Brodie, C. |
The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells |
2017 |
Oncotarget |
8 |
31785-31801 |
|
|
|
Sullivan, K.E.; Rojas, K.; Cerione, R.A.; Nakano, I.; Wilson, K.F. |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells |
2017 |
Oncotarget |
8 |
22325-22343 |
|
|
|
Glaser, T.; Han, I.; Wu, L.; Zeng, X. |
Targeted Nanotechnology in Glioblastoma Multiforme |
2017 |
Frontiers in Pharmacology |
8 |
166 |
|
